Replies to post #233792 on Biotech Values

[miljenko]

The companies currently expect to manufacture globally up to 100 million doses by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021, subject to final dose selection from their clinical trial.

All this is starting to be more than ridiculous.

They do not know what vaccine candidate will move forward, they do not know will there be any protective effects, but WHEN GOV pays the bills, lets do spending!

[DewDiligence]

BNTX sells 6.33M* ADSs @$93.00—a 5% premium to Monday’s closing price—raising $588M* in gross proceeds:

https://www.globenewswire.com/news-release/2020/07/23/2066253/0/en/BioNTech-Announces-Pricing-of-Upsized-Underwritten-Offering-and-Terms-of-Rights-Offering.html

*Assuming exercise of underwriter’s option.

[DewDiligence]

PFE/BNTX start phase-2/3 trial of COVID-19 vaccine:

https://www.businesswire.com/news/home/20200727005800/en

The vaccine selected for phase-2/3, BNT162b2, is not the one for which PFE/BNTX reported phase-1 data in early July (#msg-156682852). The reported phase-1 data were for BNT162b1, which codes for the receptor-bonding domain of SARS-CoV-2’s spike protein, while the selected vaccine, BNT162b2, codes for the entire length of the spike protein—see slide #6 at https://investors.biontech.de/static-files/c4feb567-e564-40e5-a9cf-538892af1c04 .

The above PR says PFE/BNTX selected BNT162b2 because it showed a better safety profile than BNT162b1 and it generated a broader T-cell response due to the additional epitopes. (PFE also evaluated two other vaccine candidates, BNT16a1 and BNT16c2, that were not progressed [slide #6, ibid].)

The phase-2/3 trial of BNT162b2 will enroll approximately 30,000 subjects randomized 1:1 to two 30µ doses of vaccine or (two doses of) placebo. The primary endpoint is the prevention of symptomatic COVID-19 disease (same as in MRNA’s phase-3 trial).

[DewDiligence]

PFE/BNTX ink supply agreement with EU—200M doses with an option for another 100M:

https://www.businesswire.com/news/home/20201111005405/en/Pfizer-and-BioNTech-Reach-an-Agreement-to-Supply-the-EU-With-200-Million-Doses-of-Their-BNT162b2-mRNA-Based-Vaccine-Candidate-Against-SARS-CoV-2

The price per dose in the EU order hasn’t been disclosed, but we may presume that it’s in the same ballpark as the $19.95 price paid by the US federal government (#msg-157072705).